Andrew J. Murphy
2020
In 2020, Andrew J. Murphy earned a total compensation of $11M as Executive Vice President, Research at Regeneron Pharmaceuticals, a 16% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $887,250 |
|---|---|
| Option Awards | $4,335,258 |
| Salary | $726,923 |
| Stock Awards | $5,025,288 |
| Other | $24,195 |
| Total | $10,998,914 |
Murphy received $5M in stock awards, accounting for 46% of the total pay in 2020.
Murphy also received $887.3K in non-equity incentive plan, $4.3M in option awards, $726.9K in salary and $24.2K in other compensation.
Rankings
In 2020, Andrew J. Murphy's compensation ranked 722nd out of 13,090 executives tracked by ExecPay. In other words, Murphy earned more than 94.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 722 out of 13,090 | 95th |
Division Manufacturing | 250 out of 5,621 | 96th |
Major group Chemicals And Allied Products | 79 out of 2,254 | 97th |
Industry group Drugs | 68 out of 1,954 | 97th |
Industry Pharmaceutical Preparations | 51 out of 1,459 | 97th |
Source: SEC filing on April 23, 2021.
Murphy's colleagues
We found four more compensation records of executives who worked with Andrew J. Murphy at Regeneron Pharmaceuticals in 2020.
2020
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer
2020
George Yancopoulos
Regeneron Pharmaceuticals
Chief Scientific Officer
2020
Daniel Van Plew
Regeneron Pharmaceuticals
Executive Vice President and General Manager, Industrial Operations and Product Supply
2020
Robert Landry
Regeneron Pharmaceuticals
Chief Financial Officer
News
Regeneron Pharmaceuticals Executive Vice President and General Manager, Industrial Operations and Product Supply Daniel Van Plew's 2021 pay rises 1% to $8.8M
April 21, 2022
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2020 pay jumps 531% to $135M
April 23, 2021
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2019 pay slips 19% to $21M
April 24, 2020